Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


06 junio 2014

Sapien 3 heart valve could be used in intermediate risk patients

Cardiovascular News

The 30-day results of the Sapien 3 study, which evaluated the use of the Sapien 3 transcatheter aortic valve implantation (TAVI) device in patients with aortic stenosis who were at high or intermediate surgical risk, indicate that transfemoral implantation of the valve is associated with a low rate of mortality, a low rate of stroke, and no incidences of severe paravalvular leak. This indicates that the device could be used to manage aortic stenosis patients who are at intermediate surgical risk.

06 junio 2014

Manual thrombus aspiration associated with a higher rate of direct stenting

Cardiovascular News

Diego Fernández-Rodríguez (Cardiology Department, University Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain) and others write in Circulation: Cardiovascular Interventions that patients who undergo manual thrombus aspiration prior to primary percutaneous coronary intervention (PCI) have a significantly higher rate of direct stenting and a significantly lower rate of postdilation compared with patients who do not undergo the procedure prior to primary PCI. However, manual thrombus aspiration is not associated with an improvement in long-term outcomes.

05 junio 2014

RESPOND post market registry of Lotus valve system initiated

Cardiovascular News

Boston Scientific has initiated the RESPOND post market registry to assess real world performance of the Lotus valve system. The RESPOND registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centres around the world.

04 julio 2014

Incidental findings on imaging leads to worse outcomes for prospective TAVI patients

Cardiovascular News

Refai Showkathali (Department of Cardiology, King’s College Hospital, London, UK) and others report in EuroIntervention that patients with incidental findings on computed tomography (CT) aortogram who are undergoing assessment for possible transcatheter aortic valve implantation (TAVI) are significantly less likely to receive TAVI as definitive therapy, have a significantly longer time before undergoing a TAVI procedure, and have worse overall outcomes compared with patients without incidental findings.

04 julio 2014

Transradial access predicts survival in NSTEMI patients

Cardiovascular News

According to a new study, the reduced bleeding and reduced mortality seen with the transradial approach in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) is also observed in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

02 julio 2014

CorMatrix completes enrolment of patients in RESTORE

Cardiovascular News

CorMatrix Cardiovascular and the Central Clinical Hospital of the Ministry of Interior in Warsaw (Centralny Szpital Kliniczny MSW) of Warsaw, Poland announced the successful enrolment and treatment of five patients in the first ever study evaluating the CorMatrix ECM delivered trans-epicardially for the improvement of myocardial function in patients at risk or suffering from congestive heart failure.

02 julio 2014

First European experience with ProTrack at St George’s Hospital London

Cardiovascular News

The first cases using the ProTrack Pigtail wire (Baylis Medical) in Europe were performed last month at St George’s Hospital in London. The ProTrack Pigtail wire is used during the transseptal procedure, a challenging minimally invasive technique used to cross the septum of the heart.

30 junio 2014

Corindus Vascular Robotics receives North American New Product Innovation Award in interventional cardiology

Cardiovascular News

Corindus Vascular Robotics has been named the recipient of the 2014 North American New Product Innovation Award in Interventional Cardiology. The award was established by growth partnership company Frost & Sullivan to recognise visionary innovation and product excellence. Corindus’s CorPath vascular robotic system is the first medical device to bring robotic precision and accuracy to coronary angioplasty procedures, which may improve clinical outcomes while increasing radiation protection for interventional cardiologists.

30 junio 2014

Siemens workshop enhances diagnostic confidence and workflow efficiency within ultrasound

Cardiovascular News

Siemens Healthcare recently hosted a series of echocardiography and workflow efficiency workshops across the UK. Using live demonstrations of the ACUSON SC2000, delegates were able to discover how continuous volume imaging can improve diagnostic confidence and workflow efficiency. The workshops were held in Glasgow, Manchester and London and saw experts in the field of echocardiography speak to delegates including consultan

24 junio 2014

Fortis Hospitals performs coronary artery bypass surgery through the abdomen

Cardiovascular News

In a pioneering accomplishment, doctors at Fortis Hospitals, Bangalore, India, put a 46-year-old woman suffering with coronary artery disease to quick recovery with minimally-invasive trans-abdominal Coronary Artery Bypass Graft (CABG). The procedure was performed by making only a small incision in the upper abdomen, sparing the breast bone or the chest wall completely.

20 junio 2014

Faster full strut coverage with self-apposing stent

Cardiovascular News

At EuroPCR (20–23 May, Paris, France), Robert-Jan van Geuns (Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands) reported that the results of the APPOSITION IV study indicate that a self-apposing sirolimus-eluting stent (Stentys) is associated with significantly faster full strut coverage and better apposition at four months than a balloon-expandable zotarolimus-eluting stent.

20 junio 2014

Novel anticoagulation system for PCI patients is effective at supressing ischaemic events without compromising bleeding

Cardiovascular News

Thomas J Povsic (Duke Clinical Research Institute, Duke University Medical Center, Durham, USA) and others report in Eurointervention that the novel REG1 anticoagulation system—comprised of a single-stranded RNA factor IXa inhibitor (pegnivacogin) and its reversal agent (anivamersen)—is safe and feasible for supressing both ischaemic events and thrombotic complications with a favourable bleeding profile in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.